COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

NCT04392219 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
130
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Ridgeback Biotherapeutics, LP